Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Echevarría Vargas, Ileabett M ^a   Valiyeva, Fatma ^a   Vivas Mejía, Pablo E ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MICRORNA 21; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; MESSENGER RNA; PDCD4 PROTEIN, HUMAN; RNA BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MIR 21 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARIAN CANCER CELL LINE; OVARY CANCER; PDCD4 GENE; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; APOPTOSIS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 8; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED;

EID: 84901455567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097094     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer Statistics, 2013. 63: 11-30.
2. Bast RC, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nature reviews Cancer 9: 415-428.
3. Vasey PA (2003) Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. British journal of cancer 89 Suppl 3: S23-8.
4. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2011) Molecular mechanisms of cisplatin resistance. Oncogene: 1869-1883.
5. Kikuchi Y (2001) [The mechanism of cisplatin-resistance in ovarian cancer]. Human cell 14: 115-133.
6. Sorrentino A, Liu C-G, Addario A, Peschle C, Scambia G, et al. (2008) Role of microRNAs in drug-resistant ovarian cancer cells. Gynecologic oncology 111: 478-486.
7. Slezak-Prochazka I, Durmus S, Kroesen B-J, Van den Berg A (2010) MicroRNAs, macrocontrol: regulation of miRNA processing. RNA (New York, NY) 16: 1087-1095.
8. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
9. Ma J, Dong C, Ji C (2010) MicroRNA and drug resistance. Cancer gene therapy 17: 523-531.
10. Nana-Sinkam SP, Croce CM (2013) Clinical applications for microRNAs in cancer. Clinical pharmacology and therapeutics 93: 98-104.
11. Pan X, Wang Z-X, Wang R (2010) MicroRNA-21: a novel therapeutic target in human cancer. Cancer biology & therapy 10: 1224-1232.
12. Gong C, Yao Y, Wang Y, Liu B, Wu W, et al. (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. The Journal of biological chemistry 286: 19127-19137.
13. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, et al. (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clinical cancer research 14: 2690-2695.
14. Xie Z, Cao L, Zhang J (2013) miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1 a expression in human ovarian cancer cells. Oncology letters 6: 795-800.
15. Wei NA, Liu SS, Leung THY, Tam KF, Liao XY, et al. (2009) Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Molecular cancer 8: 70.
16. Talotta F, Cimmino a, Matarazzo MR, Casalino L, De Vita G, et al. (2009) An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 28: 73-84.
17. Mudduluru G, George-William JN, Muppala S, Asangani IA, Kumarswamy R, et al. (2011) Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Bioscience reports 31: 185-197.
18. Chan JK, Blansit K, Kiet T, Sherman A, Wong G, et al. (2014) The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecologic oncology 132: 739-744.
19. Krichevsky AM, Gabriely G (2009) miR-21: a small multi-faceted RNA. Journal of cellular and molecular medicine 13: 39-53.
20. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, et al. (2008) miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. Journal of molecular biology 378: 492-504.
21. Misawa A, Katayama R, Koike S, Tomida A, Watanabe T, et al. (2010) AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncology research 19: 23-33.
22. Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ (2004) Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecologic oncology 93: 78-86. (Pubitemid 38429552)
23. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, et al. (2006) The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer biology & therapy 5: 1136-1141. (Pubitemid 44772228)
24. Skilling JS, Squatrito RC, Connor JP, Niemann T, Buller RE (1996) p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecologic oncology 60: 72-80. (Pubitemid 26028460)
25. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, et al. (2001) Molecular determinants of ovarian cancer plasticity. The American journal of pathology 158: 1279-1288. (Pubitemid 32281292)
26. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, et al. (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer research 47: 414-418. (Pubitemid 17009602)
27. Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R (2007) The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Human reproduction 22: 1304-1309. (Pubitemid 47062799)
28. Peltier HJ, Latham GJ (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA (New York, NY) 14: 844-852. (Pubitemid 351574906)
29. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nature protocols 3: 1101-1108. (Pubitemid 351818697)
30. Vivas-Mejia PE, Rodriguez-Aguayo C, Han H-D, Shahzad MMK, Valiyeva F, et al. (2011) Silencing survivin splice variant 2B leads to antitumor activity in taxane - resistant ovarian cancer. Clinical cancer research 17: 3716-3726.
31. Echevarria-Vargas I, Vivas-Mejia P (2013) Assessment of mRNA Splice Variants by qRT-PCR. Ovarian Cancer. Malek A, Tchernitsa O, editors Totowa, NJ: Humana Press. p . 171-186.
32. Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G (2009) Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. International journal of cancer 125: 264-275.
33. Kumarswamy R, Volkmann I, Thum T (2011) Regulation and function of miRNA-21 in health and disease. RNA biology 8: 706-713.
34. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, et al. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proceedings of the National Academy of Sciences of the United States of America 98: 13681-13686. (Pubitemid 33115958)
35. Leppä S, Saffrich R, Ansorge W, Bohmann D (1998) Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. The EMBO journal 17: 4404-4413. (Pubitemid 28362630)
36. Karin M (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. The Journal of biological chemistry 270: 16483-16486.
37. Lou Y, Cui Z, Wang F, Yang X, Qian J (2011) miR-21 down-regulation promotes apoptosis and inhibits invasion and migration abilities of OVCAR3 cells. Clinical and investigative medicine 34: E281.
38. Si M-L, Zhu S, Wu H, Lu Z, Wu F, et al. (2007) miR-21-mediated tumor growth. Oncogene 26: 2799-2803. (Pubitemid 46663837)
39. Lou Y, Yang X, Wang F, Cui Z, Huang Y (2010) MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. International journal of molecular medicine 26: 819-827.
40. Chen Y, Tsai Y-H, Fang Y, Tseng S-H (2012) Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. Journal of pediatric surgery 47: 1797-1805.
41. Di Leva G, Croce CM (2013) The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Frontiers in oncology 3: 153.
42. Chen Y, Zhang L, Hao Q (2013) Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. Cancer cell international 13: 86.
43. Yang H, Kong W, He L, Zhao J-J, O'Donnell JD, et al. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer research 68: 425-433. (Pubitemid 351380068)
44. Braun R, Finney R, Yan C, Chen Q-R, Hu Y, et al. (2013) Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patients. PloS one 8: e55037.
45. Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, et al. (2011) Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 32: 1607-1614.
46. Peng R-Q, Wan H-Y, Li H-F, Liu M, Li X, et al. (2012) MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N- acetylgalactosaminyltransferase 7. The Journal of biological chemistry 287: 14301-14309.
47. Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, et al. (2011) MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. Journal of human genetics 56: 270-276.
48. Van Jaarsveld MTM, Helleman J, Boersma AWM, Van Kuijk PF, Van Ijcken WF, et al. (2013) miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32: 4284-4293.
49. Integrated genomic analyses of ovarian carcinoma. (2011). Nature 474: 609-615.
50. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, et al. (2009) Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PloS one 4: e5311.
51. Vivas-Mejia P, Benito JM, Fernandez A, Han H-D, Mangala L, et al. (2010) c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clinical cancer research: 16: 184-194.